Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions

Arch Intern Med. 2012 Jul 9;172(13):1014-5. doi: 10.1001/archinternmed.2012.2335.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / economics
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / economics
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Aptamers, Nucleotide / economics
  • Aptamers, Nucleotide / therapeutic use
  • Bevacizumab
  • Comparative Effectiveness Research
  • Diabetic Retinopathy / complications*
  • Diabetic Retinopathy / drug therapy*
  • Drug Costs*
  • Evidence-Based Medicine
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy*
  • Macular Edema / etiology*
  • Off-Label Use*
  • Ranibizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins / economics
  • Recombinant Fusion Proteins / therapeutic use
  • United States
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • pegaptanib
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab